FDA Authorized Commercial Sale of Eve Exoskeleton

The personal device assists adults with spinal cord injuries with daily tasks like standing and walking.

Updated on Sept. 27, 2026 in Robotics

Isometric editorial illustration of a modular robotic leg brace, depicting the mechanical engineering and structural components of the medical device. — The FDA has granted commercial authorization for the Eve personal exoskeleton, a robotic mobility device for adults with spinal cord injuries. AI Illustration. Upload story photo >

Live Poll

Do you believe wearable robotic suits will meaningfully improve daily life for those with mobility issues?

The FDA has cleared the Eve personal exoskeleton for commercial sale in the United States. Manufactured by the French firm Wandercraft, the robotic device is designed to help adults with spinal cord injuries perform daily movements.

Why it matters

The exoskeleton aims to increase independence for individuals with limited mobility by assisting with tasks such as meal preparation and moving around the house. Coverage for the device is currently available through Medicare, veterans' health systems, and workers' compensation.

The Eve exoskeleton features 12 motors for movement and operates at a top speed of 0.25 meters per second with 4 hours of battery life. Users are restricted to a maximum height of 1.94 m and a weight of 100 kg while operating on flat, indoor surfaces.

The players

Wandercraft

This French robotics company specializes in the development of self-balancing exoskeletons for medical rehabilitation.

Food and Drug Administration

This federal agency is responsible for protecting public health by regulating medical devices sold in the United States.

The details

Technicians calibrate the device to each user's specific measurements, including leg length and joint flexibility, prior to delivery. Once operational, users navigate sitting, standing, and walking using a joystick, provided a certified caregiver remains present.

Wandercraft initiated US commercial sales of the Eve exoskeleton in September 2026.

The Tech Race

The Eve device represents an evolution in mobility technology, following the precedent established by the ReWalk personal exoskeleton in the domestic rehabilitation market. This release highlights the transition toward motorized, self-balancing systems that replace rigid, non-powered bracing.

Patients may access the device through insurance programs including Medicare and veterans' benefits to assist with daily living. Users should note the requirement for a certified caregiver and the limitation of the device to flat, indoor surfaces.

The takeaway

The Eve exoskeleton offers a new level of mobility for adults with spinal cord injuries who require assistance with household tasks. Potential users should consult their healthcare providers to determine if they meet the specific weight and height requirements for operation.